Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer

被引:22
作者
Noguchi, M
Imaizumi, K
Kawabe, T
Wakayama, H
Horio, Y
Sekido, Y
Hara, T
Hashimoto, N
Takahashi, M
Shimokata, K
Hasegawa, Y [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan
关键词
antitumor immunity; CD40; ligand; interferon-gamma; cytotoxic T lymphocyte; lung cancer;
D O I
10.1038/sj.cgt.7700320
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CD40-CD40 ligand (CD40L) interaction is an Important costimulatory signaling pathway in the crosstalk between T cells and antigen-presenting cells. This receptor-ligand system is known to be essential in eliciting strong cellular immunity. Here we demonstrate that murine lung cancer cells (3LLSA) transduced with the CD40L gene (3LLSA-CD40L) were rejected in syngeneic C57BL/6 mice, but grew in CD40-deficient mice to the same extent as control tumor cells. Immunohistochemical study showed that inflammatory cells, including CD4+, CD8+ T cells and NK cells, infiltrated Into the inoculated 3LLSA-CD40L tumor tissue. Inoculation of 3LLSA-CD40L cells into mice resulted in the induction of 3LLSA-specific cytotoxic T-cell immunity, and the growth of parental 3LLSA tumors was inhibited when 3LLSA cells were inoculated into C57BL/6 mice mixed with 3LLSA-CD40L cells or when they were rechallenged 4 weeks after 3LLSA-CD40L cells were rejected. Furthermore, co-inoculation of interferon (IFN)-gamma -transduced cells (3LLSA-IFN gamma) with 3LLSA-CD40L cells enhanced the antitumor immunity efficiently in vivo. These results indicate that the in vivo priming with CD40L- and IFN-gamma gene-transduced lung cancer cells is a promising strategy for inducing antitumor immunity in the treatment of lung cancer.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 37 条
[1]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[2]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[3]  
Bianchi R, 1999, J IMMUNOL, V163, P2517
[4]  
Biancone L, 1999, J IMMUNOL, V163, P6201
[5]  
Borges L, 1999, J IMMUNOL, V163, P1289
[6]   Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation [J].
Cella, M ;
Scheidegger, D ;
PalmerLehmann, K ;
Lane, P ;
Lanzavecchia, A ;
Alber, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :747-752
[7]   Dendritic cells infiltrating tumors cotransduced with granulocyte macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response [J].
Chiodoni, C ;
Paglia, P ;
Stoppacciaro, A ;
Rodolfo, M ;
Parenza, M ;
Colombo, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (01) :125-133
[8]   What is the real role of CD40 in cancer immunotherapy? [J].
Costello, RT ;
Gastaut, JA ;
Olive, D .
IMMUNOLOGY TODAY, 1999, 20 (11) :488-493
[9]   Effects of TGF-β on the immune system:: implications for cancer immunotherapy [J].
de Visser, KE ;
Kast, WM .
LEUKEMIA, 1999, 13 (08) :1188-1199
[10]  
Esche C, 1999, EUR J IMMUNOL, V29, P2148